Eupraxia Pharmaceuticals Inc.

Healthcare · Biotechnology · Canada

Last price 6.83 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 449.68M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company’s product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the ...